A Pilot Study of Early Postpartum Intrauterine Contraception

Unplanned Pregnancy Clinical Trial

— ImmPPIUD  

Official title:

A Pilot Study of Early Postpartum Intrauterine Contraception

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00997932
• Other study ID #: SFP3-14
• Status: Completed
• Phase: Phase 4
• First received: September 28, 2009
• Last updated: March 28, 2017
• Start date: June 2009
• Est. completion date: November 2012

Study information

• Verified date: March 2017
• Source: University of North Carolina, Chapel Hill
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a prospective clinical trial of ultrasound guided intrauterine contraception insertion 10 minutes - 48 hours after vaginal delivery of single infant. A six month follow-up will entail three follow-up visits; 4-6 weeks, 3 months, and 6 months.

The objective of this study is to measure intrauterine device (IUD) expulsion and the feasibility of conducting a future clinical trial to evaluate placement of the levonorgestrel-releasing intrauterine contraceptive 10 minutes - 48 hours postpartum.

Description:

This was a single arm cohort study of women who desired to receive a levonorgestrel releasing intrauterine system (LNG-IUS) within 48 hours of uncomplicated vaginal delivery.

Women were enrolled during a prenatal care visit when they reported they desired to use the LNG-IUS after the birth of their infant.

Forty women stated enrolled in the study prior to labor, and baseline data were obtained. After delivery 29 women remained both interested in the study and were still eligible to receive the LNG-IUS prior to discharge from the hospital.

Of the 29 women who received the LNG-IUS prior to discharge from the hospital 11 women had an LNG-IUS expulsion prior to 6 months postpartum.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: November 2012
• Est. primary completion date: October 2010
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 21 Years to 45 Years

Eligibility

Inclusion Criteria:

• Currently pregnant with a single gestation of at least 27 completed weeks estimated gestational age, with no complications of pregnancy including, but not limited to, preeclampsia, non-gestational diabetes, anemia.

• Desires to use intrauterine contraception (IUD) after delivery

• Anticipates having a vaginal delivery

• No intention to leave the area 7 months after enrollment

• Able to consent to participate in the study in English

• Has no known uterine anomalies

• Has no allergies to any components of the intrauterine contraception

Exclusion Criteria:

• Prior cesarean delivery

• Having been treated for pelvic inflammatory disease within 3 months prior to the start of the pregnancy

• Allergic to betadine

• Allergy to lidocaine

• Medical or personal conditions which in the judgment of study staff contradict participation in the study

• Any contraindications to use of the levonorgestrel-releasing intrauterine contraceptive system which includes: known or suspected breast carcinoma, acute liver disease or liver tumor, history of ectopic pregnancy, cervical cancer or carcinoma in situ

• After enrollment, and after delivery of the infant but before IUD insertion subjects will be excluded by checking with the attending obstetric physician and/or obstetric medical chart for the following:

• Endometritis or chorioamnionitis during the intrapartum period

• Membranes ruptured for greater than 24 hours prior to delivery

• Fever greater than or equal to 38C

• The need to use additional medications other than pitocin and/or misoprostol to control postpartum bleeding

Related Conditions & MeSH terms

• Unplanned Pregnancy

Intervention

Drug:
• Levonorgestrel-Releasing Intrauterine Contraceptive System (LNG-IUS), 52 Mg, 5 Year Duration
Levonorgestrel-Releasing Intrauterine Contraceptive System, 52 Mg, 5 Year Duration Postpartum placement of LNG-IUS within 10 minutes - 48 hours

Locations

Country	Name	City	State
United States	University of North Carolina at Chapel Hill	Chapel Hill	North Carolina

Sponsors (1)

Lead Sponsor	Collaborator
University of North Carolina, Chapel Hill

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	IUD Expulsion	Expulsion of the LNG-IUS	From time of insertion to final study date which is 6 months after IUD insertion.